#StopOrNot - Twitter Hashtag

almost 2 years ago

#StopOrNot #ESCCongress #Friday #Hotline ➡️discontinuation of a renin-angiotensin system inhibitor (RASI) before non-cardiac surgery resulted in a similar rate of major post-operative complications compared with RASI continuation. ➡️Rates of hypotension during non-cardiac surgery were higher and longer in the continuation group but this did not translate into a higher risk of post-operative complications. ➡️Given the similar rate of post-operative complications, the choice of continuation/discontinuation could be made based on individual patient needs. 🔗 https://t.co/ipgpFjSu3r @mirvatalasnag @DBelardoMD @HeartOTXHeartMD @DrToniyaSingh

purviparwani's tweet photo. #StopOrNot
#ESCCongress
#Friday #Hotline

➡️discontinuation of a renin-angiotensin system inhibitor (RASI) before non-cardiac surgery resulted in a similar rate of major post-operative complications compared with RASI continuation.

➡️Rates of hypotension during non-cardiac surgery were higher and longer in the continuation group but this did not translate into a higher risk of post-operative complications.

➡️Given the similar rate of post-operative complications, the choice of continuation/discontinuation could be made based on individual patient needs.

🔗 https://t.co/ipgpFjSu3r

@mirvatalasnag @DBelardoMD @HeartOTXHeartMD @DrToniyaSingh

Dr. Purvi Parwani

@purviparwani

almost 2 years ago

#ABYSS trial #Friday #Hotline #ESCCongress Beta-blocker interruptions post-MI 💊 Among patients with a previous myocardial infarction, interruption of long-term beta-blocker therapy was not found to be noninferior to continuation with respect to adverse events at a median of 3 years. 💊 n= 3,698 patients (mean age 63.5 years; 82.8% male) with a history of MI at least 6 months (Patients with heart failure, LVEF (< 40%)excluded) 💊 2/3 with STEMI and 95% with PCI 💊 follow-up of 3.0 years 💊 the primary outcome of death, nonfatal MI, nonfatal stroke, or hospitalization for cardiovascular causes- in 23.8% of patients without BB and in 21.1% of those on BB - failed to meet noninferiority criteria for the combined primary endpoint 💊 Stopping beta-blocker ➡️failed to improve quality of life, more hospitalizations for CV causes, more angina, higher HR and BP Await results from DANBLOCK, SMART-DECISION, BETAMI, REBOOT! https://t.co/Q2BoPbPpHc @mirvatalasnag @HeartOTXHeartMD @DBelardoMD @AnastasiaSMihai @mmamas1973 @DLBHATTMD @RonBlankstein

purviparwani's tweet photo. #ABYSS trial #Friday #Hotline
#ESCCongress

Beta-blocker interruptions post-MI

💊 Among patients with a previous myocardial infarction, interruption of long-term beta-blocker therapy was not found to be noninferior to continuation with respect to adverse events at a median of 3 years.

💊 n= 3,698 patients (mean age 63.5 years; 82.8% male) with a history of MI at least 6 months
(Patients with heart failure, LVEF (< 40%)excluded)
💊 2/3 with STEMI and 95% with PCI
💊 follow-up of 3.0 years

💊 the primary outcome of death, nonfatal MI, nonfatal stroke, or hospitalization for cardiovascular causes- in 23.8% of patients without BB and in 21.1% of those on BB - failed to meet noninferiority criteria for the combined primary endpoint

💊 Stopping beta-blocker ➡️failed to improve quality of life, more hospitalizations for CV causes, more angina, higher HR and BP

Await results from DANBLOCK, SMART-DECISION, BETAMI, REBOOT!

https://t.co/Q2BoPbPpHc

@mirvatalasnag @HeartOTXHeartMD @DBelardoMD @AnastasiaSMihai @mmamas1973 @DLBHATTMD @RonBlankstein

1

43

12

8

10K

4

34

12

5

10K

Matthieu Legrand @matthieulegrand

over 7 years ago

45 patients enrolled last month in the #STOPorNOT trial! Thanks to the patients and all the investigators ⁦@SFAR_ORG⁩ @EtienneGayat⁩ @ini-crct ⁦@APHP⁩ ⁦@StLouis_Larib⁩